Rehabilitative treatment in peripheral artery disease: Protocol application and follow-up

Minerva Cardioangiologica

Volumn 58, Issue 5, 2010, Pages 551-565

  Riccioni, C ^a   Sarcinella, R ^a   Izzo, A ^a   Palermo, G ^a   Liguori, M ^a   Caliumi, C ^a   Carloni, E ^a   Paolucci, A M ^a   D'Andrea, P ^a   Pompili, S ^a  

^a RM B Local Health Unit   (Italy)

Author keywords

Critical limb ischemia; Diabetes mellitus; Peripheral vascular diseases

Indexed keywords

PROPIONYLCARNITINE;

ADULT; AGED; AMPUTATION; ANKLE BRACHIAL INDEX; ARTERY BLOOD FLOW; ARTERY DISEASE; ARTICLE; BICYCLE; CLAUDICATION; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART REHABILITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIMETRY; QUESTIONNAIRE; TREADMILL; WALKING;

AGED; CARDIOTONIC AGENTS; CARNITINE; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; EXERCISE THERAPY; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISCHEMIA; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; REGIONAL BLOOD FLOW; WALKING;

EID: 79251498638     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Vander AJ, Sherman JH, Luciano DS. Il muscolo. In: di Pampero PE, Veicsteinas A, editors. Fisiologia dell'uomo. I meccanismi funzionali del corpo. Milano: ediermes; 2002. p. 214-54.
2. Marci M. La riabilitazione. In: Marci M, Raffa S, editors. L'arteriopatia obliterante aterosclerotica degli arti inferiori. Roma: Cesi; 1999. p. 247-53.
3. Hiatt WR, Regensteiner JG, Hargarten ME. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990;81;602-9.
4. Riccioni C, Sarcinella R, Izzo A, Palermo G. Effects of L-propyonil carnitine in patients affected by peripheral artheriopathy. Int Ang 2004;23:40.
5. Rudofsky GU. Kompaktwissen Angiologie. In: Arteriopatie ostruttive croniche. I ed. Italiana. Palermo: Medical Books; 1989. p. 296-8.
6. Riccioni C, Sarcinella R, Izzo A, Palermo G. Riabilitazione vascolare associata a terapia farmacologia metabolica:loro utilizzo nelle arteriopatie al II stadio. Min Cardioang 2006;54(Suppl 1 al N.6):279-81.
7. Riccioni C, Sarcinella R, Izzo A, Palermo G. Evaluation of the efficacy of propyonil-L-carnitine versus pulsed muscular compressions in diabetic and non diabetic patients affected by obliteratine artheriopathy Leriche stage II. Intern Angiol 2008;27:253-9.
8. Margolis J, Barron J, Grochulski D. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Managed Care Pharm 2005,11;727-34.
9. Shammas N. Epidemiology, classification and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag 2007;3:229-34. (Pubitemid 46860711)
10. Mukherjee D, Yadav JS. Update on peripheral vascular diseases: from smoking to stenting. Cleve Clin J Med 2001;68:723-34. (Pubitemid 32744530)
11. Cipolla MJ, Nicoloff A, Rebello T, Amato A, Porter JM. Propyonil-L-carnitine dilates human subcutaneous arteries through an endothelium dependent mechanism. J Vasc Surg 1998;29:1097-103.
12. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-1-carnitine in intermittent claudication. J Am Coll Cardiol 1999;34:1618-24. (Pubitemid 29528679)
13. Hulsmann WC, Dubelaar ML. Carnitine requirement of vascular endothelial and smooth muscle cells in imminent ischemia. Molec Cellul Biochemistry 1992;116:125-9.
14. Dal Lago A, De Martini D, Flore R, Gaetani E, Gasbarrini A, Gerardino L et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double blind clinical trial. Drugs Exptl Clin Res 1999;25:29-36. (Pubitemid 29199590)
15. Binienda Z, Virmani A. The mitochondriotropic effects of L-carnitine and its esters in the central nervous system. Curr Med Chem 2003;3:275-82.
16. Pola P, de Martini D, Gerardino L. The action of propionil-L-carnitine on the vasal endothelium: incresed t-PA synthesis and a decrease in the activity of PAI-1. A preliminary study. Drugs Expd Clin Res 1992;18:343-8.
17. Pola P, Flore R. Rheological activity of propyonil-1-carnitine. Drugs Exp Clin Res 1991;17:191-6.
18. Capecchi PL, Pasini FL. Carnitine increases plasma levels of adenosine and ATP in humans. Vasc Med 1997;2:77-81.
19. Van Hinsberg V, Scheffer M. Effects of propyonil carnitine on human endothelial cells. Cardiovasc Drugs Ther 1991;5:97-105.
20. Hulsmann WC. Biochemical profile of propyonilcarnitine. Cardiovasc Drugs 1991;5:7-9.
21. Bertelli G, Giovannini L, Galmozzi G. Protective role of propyonilcarnitine in vascular disorders experimentally induced by endothelin (Et-1) serotonin and K carrageenan. Drugs Exp Clin Res 1993;19:7-11.
22. De Marchi S, Prior M, Rigoni A. Microcirculation and endothelium in CLI treated with 1-propionil carnitine. Intern Ang 2004;23:195.
23. Taylor DJ, Amato A, Hands L. Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31p magnetic resonance spectroscopy. A phase II open study. Vasc Med 1996;1:241-5.
24. Bertelli A, Giovannini L. Inhibition of istamine-release and pressure increase induced by endothelin 8et-1) in isolated rat kidneys treated with propionylcarnitine. Drugs Exp Clin Res 1992;18:349-53.
25. Mauriello A, Sangiorgi G, Orlandi A. Effect of long term treatment with propyonyl 1 carnitine on smooth muscle cell polyploidy in spontaneously hypertensive rats. Hypertension 1996;28:177-82.
26. Brevetti G, Diehm C. European multicenter study on propyonil-1-carnitine in intermittent claudication. J Amer Coll Cardiol 1999;34:1618-24. (Pubitemid 29528679)
27. Barker GA, Green S, Askew CD. Effect of propyonil-1-carnitine on exercise performance in peripheral arteries disease. Med Sci Sports Exer 2001;33:1415-22.
28. Hiatt WR. Carnitine and peripheral arteries disease. Ann N Y Acad Sci 2004;1033:92-8.
29. Carlon R, Olivieri A, Benacchio L. Risultati a breve e medio termine dei parametri funzionali dopo singolo ciclo di training fasico controllato in soggetti con claudicatio. Monaldi Arch Chest Dis 2008;70:76-83.